Letter/Communication
Is Caplacizumab Effective in All Patients with iTTP?
NEJM journal watch. Oncology & hematology
08/29/2024
Abstract
In a post-hoc analysis of the HERCULES trial, caplacizumab, a nanobody that inhibits von Willebrand factor–platelet interaction, demonstrated efficacy regardless of iTTP history, disease severity, or initial immunosuppression regimen, but questions remain about long-term remission.
Details
- Title: Subtitle
- Is Caplacizumab Effective in All Patients with iTTP?
- Creators
- Anjali Sharathkumar
- Resource Type
- Letter/Communication
- Publication Details
- NEJM journal watch. Oncology & hematology
- Publisher
- Massachusetts Medical Society
- ISSN
- 2330-0426
- Language
- English
- Date published
- 08/29/2024
- Academic Unit
- Stead Family Department of Pediatrics; Hematology/Oncology
- Record Identifier
- 9984699049102771
Metrics
11 Record Views